Drugs / HD-TIV
HD-TIV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02936180 Comparator | Oct 2016 → Jul 2018 | rheumatoid arthritis | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HD-TIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02936180 ↗ |
| Known as | FLUZONE High Dose Trivalent Inactivated Influenza Vaccine | “Patients will receive one dose of FLUZONE® High Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)” NCT02936180 ↗ |
| Modality | Vaccine | “high-dose trivalent inactivated influenza vaccine (HD-TIV)” NCT02936180 ↗ |